To build upon this body of work and test the advantages of multiple‐component co‐delivery on NPs, we have engineered E2 protein NPs that can conjugate and deliver two TLR agonists (flagellin [a TLR5 agonist] and CpG [a TLR9 agonist]) and influenza H5 antigen on a single NP, attached in a way that displays each component in its native‐pathogenic orientation. The gene discussed is TLR9; the disease is influenza.